Neoadjuvant Breast Cancer Treatment as a Sensitive Setting for Trastuzumab Biosimilar Development and Extrapolation

References

• Cho HS , MasonK, RamyarKXet al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature421, 756–760 (2003).
   PubMed Web of Science ®Google Scholar
• US FDA prescribing information for Herceptin® . www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf
   Google Scholar
• Slamon DJ , Leyland-JonesB, ShakSet al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344, 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• EMA Summary of product characteristics for Herceptin . www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf
   Google Scholar
• Piccart-Gebhart MJ , ProcterM, Leyland-JonesBet al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353, 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Romond EH , PerezEA, BryantJet al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353, 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Slamon D , EiermannW, RobertNet al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med.365, 1273–1283 (2011).
   PubMed Web of Science ®Google Scholar
• Bang YJ , Van CutsemE, FeyereislovaAet al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet376, 687–697 (2010).
   PubMed Web of Science ®Google Scholar
• Gianni L , EiermannW, SemiglazovVet al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet375, 377–384 (2010).
   PubMed Web of Science ®Google Scholar
• Gianni L , EiermannW, SemiglazovVet al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. doi: 10.1016/S1470–2045(14)70080–4 (2014) ( Epub ahead of print).
   Google Scholar
• Ismael G , HeggR, MuehlbauerSet al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol.13, 869–878 (2012).
   PubMed Web of Science ®Google Scholar
• Hirsch BR , LymanGH. Biosimilars: are they ready for primetime in the United States?J. Natl Compr. Canc. Netw.9, 934–942 (2011).
   PubMed Web of Science ®Google Scholar
• Jelkmann W . Biosimilar epoetins and other ‘follow-on’ biologics: update on the European experiences. Am. J. Hematol.85, 771–780 (2010).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency . Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues (2012).
   Google Scholar
• Boven K , StrykerS, KnightJet al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int.67, 2346–2353 (2005).
   PubMed Web of Science ®Google Scholar
• Schellekens H . Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant.20(Suppl. 6), vi3–vi9 (2005).
   PubMedGoogle Scholar
• Kuhlmann M , CovicA. The protein science of biosimilars. Nephrol. Dial. Transplant.21(Suppl. 5), v4–v8 (2006).
   PubMed Web of Science ®Google Scholar
• Mellstedt H , NiederwieserD, LudwigH. The challenge of biosimilars. Ann. Oncol.19, 411–419 (2008).
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration . Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (2012).
   Google Scholar
• US Food and Drug Administration . Guidance for Industry: Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an end point to Support Accelerated Approval (2012).
   Google Scholar
• Cortazar P , ZhangL, UntchMet al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet doi: 10.1016/S0140–6736(13)62422–8 (2014) ( Epub ahead of print).
   Google Scholar
• von Minckwitz G , UntchM, BlohmerJUet al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol.30, 1796–1804 (2012).
   PubMed Web of Science ®Google Scholar
• Burzykowski T , BuyseM, Piccart-GebhartMJet al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J. Clin. Oncol.26, 1987–1992 (2008).
   PubMed Web of Science ®Google Scholar
• Cook JR , StefanskiLA. Simulation-extrapolation estimation in parametric measurement error models. J. Am. Stat. Assoc.89, 1314–1328 (1994).
   Web of Science ®Google Scholar
• Hegg R , PienkowskiT, ChenS-Tet al. Immunogenicity of trastuzumab intravenous and subcutaneous formulations in the Phase III HannaH study. Poster presentation 232P, ESMO, Vienna, Austria, 28 September–2 October 2012.
   Google Scholar
• Gianni L , RomieuGH, LichinitserMet al. AVEREL: a randomized Phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J. Clin. Oncol.31, 1719–1725 (2013).
   PubMed Web of Science ®Google Scholar
• Baselga J , CortésJ, KimS-Bet al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med.366, 109–119 (2012).
   PubMed Web of Science ®Google Scholar
• Valero V , ForbesJ, PegramMDet al. Multicenter Phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J. Clin. Oncol.29, 149–156 (2011).
   PubMed Web of Science ®Google Scholar
• Wardley AM , PivotX, Morales-VasquezFet al. Randomized Phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J. Clin. Oncol.28, 976–983 (2010).
   PubMed Web of Science ®Google Scholar
• Hurvitz SA , DirixL, KocsisJet al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol.31, 1157–1163 (2013).
   PubMed Web of Science ®Google Scholar
• Robert N , Leyland-JonesB, AsmarLet al. Randomized Phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol.24, 2786–2792 (2006).
   PubMed Web of Science ®Google Scholar
• Baselga J , ManikhasA, CortésJet al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann. Oncol.25, 592–598 (2014).
   PubMed Web of Science ®Google Scholar
• Untch M , RezaiM, LoiblSet al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the Geparquattro study. J. Clin. Oncol.28, 2024–2031 (2010).
   PubMed Web of Science ®Google Scholar
• von Minckwitz G , RezaiM, FaschingPAet al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40‐‐GeparQuattro). Ann. Oncol.25, 81–89 (2014).
   PubMed Web of Science ®Google Scholar
• Wolbink GJ , AardenLA, DijkmansBA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr. Opin. Rheumatol.21, 211–215 (2009).
   PubMed Web of Science ®Google Scholar
• Chirmule N , JawaV, MeibohmB. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J.14, 296–302 (2012).
   PubMed Web of Science ®Google Scholar